RxDoctor Payments Data

Kristen Osborne

Gerontology · Montgomery, ALNPI 1972948032

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,584, 3.5 times the $455 reported in 2021.

$4,738in general payments, 2019–2025

Across 248 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$443
  • Bristol Myers Squibb$415
  • Novartis$358
  • Incyte Corporation$323
  • AstraZeneca$309
  • Regeneron Healthcare Solutions, Inc.$248
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$4,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,738 in reported general payments places this provider in the 85th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$35,916
Medicare patients
300
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban38$28,840
EliquisApixaban39$24,420
Exemestane105$21,142
Letrozole62$1,263
ValacyclovirValacyclovir Hcl12$916
Anastrozole25$511
Hydroxyurea15$503
Potassium Chloride24$386
Levothyroxine Sodium36$381
Bicalutamide14$328
Fluconazole15$324
Dexamethasone12$174
Omeprazole19$173
Prednisone21$122
Ondansetron OdtOndansetron13$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$443$28,84038 claims
PfizerEliquis$132$24,42039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 gerontology providers in Alabama.

Other gerontology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →